Jack Pasini
Direktor/Vorstandsmitglied bei Oligomerix, Inc.
Aktive Positionen von Jack Pasini
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Oligomerix, Inc.
 Oligomerix, Inc. Drugstore ChainsRetail Trade Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY. | Direktor/Vorstandsmitglied | 18.10.2010 | - |
| Corporate Officer/Principal | 14.10.2010 | - |
Karriereverlauf von Jack Pasini
Ehemalige bekannte Positionen von Jack Pasini
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | - | - |
Ausbildung von Jack Pasini
| Merrimack College | Undergraduate Degree |
| Fairleigh Dickinson University | Masters Business Admin |
Statistik
International
| Vereinigte Staaten | 5 |
Operativ
| Corporate Officer/Principal | 2 |
| Director/Board Member | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Consumer Services | 3 |
| Retail Trade | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Oligomerix, Inc.
Oligomerix, Inc. Drugstore ChainsRetail Trade Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY. | Retail Trade |
- Börse
- Insiders
- Jack Pasini
- Erfahrung
